Looking an the Trial Committee. Prof Michael Wall. An expert in...

Looking an the Trial Committee. Prof Michael Wall. An expert in IIH though more so for Invex think he is a key opinion leader for perimetric mean deviation and visual fields in the US. I think he is going to be an asset in future discussions with the FDA given the PMD endpoint suggestion.

Susan Mollan. Works with Alex Sinclair and has done for sometime at the University of Birmingham. Where we haven’t seen insider buying from IXC executive (prior discussed had on this forum noting reasons and Tom’s loose commentary about this), Dr Mollan buying would be bullish for us. I wonder if she had a share holding…. maybe not allowed? Not sure about this.

Appointments of committee members seem not only to be expert but strategic. Look at the geographic dispertion:
UK, US, Germany, Italy, Aus & NZ.

Should the trial be successful, I feel this geographical dispersement helps penetrate the market / market awareness worldwide.